CD62L specific lentiviral vector particle for targeted transduction of T cell subsets

US12018273B2 · kind B2 · utility

Assignee

• Miltenyi Biorec B V. Co., KG · DE

Inventors

• Thomas Schaser · Rösrath, DE
• Andrew Kaiser · Moitzfeld, DE
• Laura Kapitza · Moitzfeld, DE
• Jessica HARTMANN · Moitzfeld, DE
• Frederic Thalheimer · Moitzfeld, DE
• Christian Buchholz · Gütersloh, DE

Key dates

• Filing date: Sep 2, 2021
• Grant date: Jun 25, 2024
• Expiry date: Nov 1, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2810/859
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a composition comprising i) a pseudotyped retroviral vector particle comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its original receptors and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for CD62L, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and T cells expressing CD62L. Alternatively, when said polypeptide comprising an antigen binding domain is specific for a tag of a tagged polypeptide instead of the antigen binding domain specific for CD62L, wherein said tagged polypeptide binds specifically to CD62L, then the composition comprises further said tagged polypeptide.